Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I
Hematology Disease Topics & Pathways:
Combination therapy, Research, Clinical Practice (Health Services and Quality), Clinical Research, Real-world evidence, Treatment Considerations
Patients and methods: We retrospectively analyzed cases with R/R APL who received VEN plus arsenics and ATRA based regimen at our institution from July 2021 to December 2023. During the reinduction cycle, patients received 0.15 mg/kg/day intravenous infusion of Arsenic trioxide or oral RIF daily 60 mg/kg/day. ATRA was administered 25 mg/m2/day. VEN was administered using a daily ramp-up strategy (100 mg on day 2, 200 mg on day 3, and 400 mg on days 4–28). The last date of follow-up for this analysis was May 2024.
Results: Thirty-one patients with R/R APL were enrolled, 10 patients has co-occurred with CNS relapse, and 1 patient with CNS relapse only. Four patients had ≥ 2 therapies. All patients had prior exposure to arsenics and ATRA. The median age was 44 years (ranges, 18-72).
After once cycle of reinduction, the overall response rate (complete remission/complete remission with incomplete count recovery) was 97% (30 of 31), CR was achieved in 27 patients. No early death was occurred. Side effects were manageable. With the median follow-up of 15 month, the 1-year event-free survival and overall survival rates is 78.7% and 96.7%, respectively.
Conclusions: Our results showed that the combination of VEN plus arsenics and ATRA appeared to be a highly effective therapy option for patients with R/R APL, and underline its potential activity also in patients with CNS involvement.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts